Skip to main content
PMC home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1992;1(3):183–190. doi: 10.1155/S0962935192000280

Interactions between platelet activating factor and eicosanoids during endotoxic shock in anaesthetized pigs

T Mózes 1,✉, F J Zijlstra 2, J P C Heiligers 2
PMCID: PMC2365336  PMID: 18475459

Abstract

The effects of platelet activating factor (PAF) on eicosanoid release during endotoxic shock was investigated in anaesthetized pigs receiving 5 μg kg−1 Escherichia coli endotoxin (LPS) into the superior mesenteric artery over a 60 min period, by measuring plasma levels of a variety of mediators. Fifteen of the 31 animals infused with LPS and not treated with BN 52021, a PAF receptor antagonist, died within 30 min after the commencement of LPS infusion (non-survivors), while the other 16 survived the experimental period of 3 h, though in a state of shock (survivors). No alterations were observed in plasma concentrations of eicosanoids in the non-survivors. A significant, though transient, increase in eicosanoid concentrations occurred only in the survivors. Treatment with BN 52021 (4 mg kg-1, i.v.) injected 5 min prior to LPS infusion, failed to exert any effect on the survival rate. However, pretreatment with BN 52021 prevented circulatory collapse in the survivors and reduced the concentration of cyclooxygenase enzyme products, without affecting LTB4 release. Exogenous administration of PAF (0.01 μg kg−1) caused hypotension and increased TXB2 levels although 6-keto PGF1α and LTB4 concentrations were unchanged. The data suggest that prostanoid formation may be secondary to PAF release in circulatory collapse evoked by LPS infusion in survivors, and give further support to the suggestion that PAF prostanoid interaction is important during endotoxic shock. However, their role in early death seems to be negligible, indicating the importance of other mediators.

Full Text

The Full Text of this article is available as a PDF (750.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ball H. A., Cook J. A., Wise W. C., Halushka P. V. Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock. Intensive Care Med. 1986;12(3):116–126. doi: 10.1007/BF00254925. [DOI] [PubMed] [Google Scholar]
  2. Bessin P., Bonnet J., Apffel D., Soulard C., Desgroux L., Pelas I., Benveniste J. Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. Eur J Pharmacol. 1983 Jan 21;86(3-4):403–413. doi: 10.1016/0014-2999(83)90190-5. [DOI] [PubMed] [Google Scholar]
  3. Beusenberg F. D., van Schaik A., van Amsterdam J. G., Bonta I. L. Involvement of eicosanoids in platelet-activating factor-induced modulation of adenylyl cyclase activity in alveolar macrophages. J Lipid Mediat. 1991 May-Jun;3(3):301–309. [PubMed] [Google Scholar]
  4. Braquet P., Paubert-Braquet M., Bourgain R. H., Bussolino F., Hosford D. PAF/cytokine auto-generated feedback networks in microvascular immune injury: consequences in shock, ischemia and graft rejection. J Lipid Mediat. 1989 Mar-Apr;1(2):75–112. [PubMed] [Google Scholar]
  5. Braquet P., Touqui L., Shen T. Y., Vargaftig B. B. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987 Jun;39(2):97–145. [PubMed] [Google Scholar]
  6. Chilton F. H., Cluzel M., Triggiani M. Recent advances in our understanding of the biochemical interactions between platelet-activating factor and arachidonic acid. Lipids. 1991 Dec;26(12):1021–1027. doi: 10.1007/BF02536495. [DOI] [PubMed] [Google Scholar]
  7. Chung K. F., Aizawa H., Leikauf G. D., Ueki I. F., Evans T. W., Nadel J. A. Airway hyperresponsiveness induced by platelet-activating factor: role of thromboxane generation. J Pharmacol Exp Ther. 1986 Mar;236(3):580–584. [PubMed] [Google Scholar]
  8. Dembinska-Kiec A., Peskar B. A., Muller M. K., Peskar B. M. The effects of platelet-activating factor on flow rate and eicosanoid release in the isolated perfused rat gastric vascular bed. Prostaglandins. 1989 Jan;37(1):69–91. doi: 10.1016/0090-6980(89)90033-6. [DOI] [PubMed] [Google Scholar]
  9. Fletcher J. R., DiSimone A. G., Earnest M. A. Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia. Ann Surg. 1990 Mar;211(3):312–316. [PMC free article] [PubMed] [Google Scholar]
  10. Hsueh W., Gonzalez-Crussi F., Arroyave J. L. Platelet-activating factor-induced ischemic bowel necrosis. An investigation of secondary mediators in its pathogenesis. Am J Pathol. 1986 Feb;122(2):231–239. [PMC free article] [PubMed] [Google Scholar]
  11. Lefer A. M. Prostacyclin, high density lipoproteins, and myocardial ischemia. Circulation. 1990 Jun;81(6):2013–2015. doi: 10.1161/01.cir.81.6.2013. [DOI] [PubMed] [Google Scholar]
  12. Lefer A. M. Significance of lipid mediators in shock states. Circ Shock. 1989 Jan;27(1):3–12. [PubMed] [Google Scholar]
  13. Moore J. M., Earnest M. A., DiSimone A. G., Abumrad N. N., Fletcher J. R. A PAF receptor antagonist, BN 52021, attenuates thromboxane release and improves survival in lethal canine endotoxemia. Circ Shock. 1991 Sep;35(1):53–59. [PubMed] [Google Scholar]
  14. Mózes T., Ben-Efraim S., Tak C. J., Heiligers J. P., Saxena P. R., Bonta I. L. Serum levels of tumor necrosis factor determine the fatal or non-fatal course of endotoxic shock. Immunol Lett. 1991 Feb;27(2):157–162. doi: 10.1016/0165-2478(91)90144-y. [DOI] [PubMed] [Google Scholar]
  15. Mózes T., Heiligers J. P., Tak C. J., Zijlstra F. J., Ben-Efraim S., Saxena P. R., Bonta I. L. Platelet activating factor is one of the mediators involved in endotoxic shock in pigs. J Lipid Mediat. 1991 Nov;4(3):309–325. [PubMed] [Google Scholar]
  16. Mózes T., Wieszt E. Intestinal and arterial plasma thromboxane and prostacyclin levels in shock: effects of indomethacin. J Surg Res. 1989 Dec;47(6):482–486. doi: 10.1016/0022-4804(89)90124-8. [DOI] [PubMed] [Google Scholar]
  17. Mózes T., Wieszt E., Zahajszky T. Role of PGF2 alpha in the superior mesenteric artery-induced shock. J Surg Res. 1989 Dec;47(6):476–481. doi: 10.1016/0022-4804(89)90123-6. [DOI] [PubMed] [Google Scholar]
  18. Mózes T., Zijlstra F. J., Heiligers J. P., Saxena P. R., Bonta I. L. Sequential release of eicosanoids during endotoxin-induced shock in anesthetized pigs. Prostaglandins Leukot Essent Fatty Acids. 1991 Apr;42(4):209–216. doi: 10.1016/0952-3278(91)90085-j. [DOI] [PubMed] [Google Scholar]
  19. Mózes T., Zijlstra F. J., Heiligers J. P., Tak C. J., Ben-Efraim S., Bonta I. L., Saxena P. R. Sequential release of tumour necrosis factor, platelet activating factor and eicosanoids during endotoxin shock in anaesthetized pigs: protective effects of indomethacin. Br J Pharmacol. 1991 Nov;104(3):691–699. doi: 10.1111/j.1476-5381.1991.tb12490.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sánchez-Crespo M., Alonso F., Iñarrea P., Alvarez V., Egido J. Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism. Immunopharmacology. 1982 Apr;4(2):173–185. doi: 10.1016/0162-3109(82)90019-4. [DOI] [PubMed] [Google Scholar]
  21. Voelkel N. F., Worthen S., Reeves J. T., Henson P. M., Murphy R. C. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science. 1982 Oct 15;218(4569):286–289. doi: 10.1126/science.7123233. [DOI] [PubMed] [Google Scholar]
  22. Zijlstra F. J., Vincent J. E. Determination of leukotrienes and prostaglandins in [14C] arachidonic acid labelled human lung tissue by high-performance liquid chromatography and radioimmunoassay. J Chromatogr. 1984 Nov 9;311(1):39–50. doi: 10.1016/s0378-4347(00)84689-7. [DOI] [PubMed] [Google Scholar]
  23. Zimmerman J. J. Therapy for overwhelming sepsis--clues for treating disease and not just the symptoms. Crit Care Med. 1990 Jan;18(1):118–119. doi: 10.1097/00003246-199001000-00025. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES